Holen Sie sich die Stockscreener-App
39.71
5.90%
1.99
Handel nachbörslich:
39.71
Schlusskurs vom Vortag:
$37.72
Offen:
$38.35
24-Stunden-Volumen:
438.06K
Relative Volume:
1.30
Marktkapitalisierung:
$1.90B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-107.28M
KGV:
-15.25
EPS:
-2.6031
Netto-Cashflow:
$-80.71M
1W Leistung:
+16.22%
1M Leistung:
+9.26%
6M Leistung:
+35.73%
1J Leistung:
+269.17%
1-Tages-Spanne:
$37.67
$40.40
1-Wochen-Bereich:
$33.85
$40.40
52-Wochen-Spanne:
$7.73
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Firmenname
Rapport Therapeutics Inc
Sektor
Branche
Telefon
857-321-8020
Adresse
99 HIGH STREET, BOSTON
Compare RAPP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
39.71 | 1.80B | 0 | -107.28M | -80.71M | -2.6031 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Strong Buy |
| 2026-02-02 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2025-09-16 | Eingeleitet | Truist | Buy |
| 2025-08-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-08 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-07-02 | Eingeleitet | Jefferies | Buy |
| 2024-07-02 | Eingeleitet | Stifel | Buy |
| 2024-07-02 | Eingeleitet | TD Cowen | Buy |
Alle ansehen
Rapport Therapeutics Inc Aktie (RAPP) Neueste Nachrichten
Rapport Therapeutics Inc. (RAPP) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock GainProduct Revenue Analysis - Newser
Rapport Therapeutics (RAPP) Gains 2.7% as Price Approaches Key Resistance LevelValue Factor - Newser
RAPP Maintains Buy Rating -- Price Target Raised to $65.00 by BT - GuruFocus
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
Rapport Therapeutics to Participate in the Jefferies Global - GlobeNewswire
RAPP Assumes Buy Rating with Price Target Raised to $56.00 by Tr - GuruFocus
Truist Financial Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $56 - Moomoo
Rapport Therapeutics Inc (RAPP) - MSN
Truist assumes Rapport Therapeutics stock with buy on epilepsy drug By Investing.com - Investing.com Canada
Truist Financial Initiates Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $56 - Moomoo
Analyst Lifts RAPT Therapeutics Price Target to $56 and Reiterates Buy on RAP-219 Seizure Data Upside - TipRanks
Trading the Move, Not the Narrative: (RAPP) Edition - Stock Traders Daily
Will Narrowing Losses And Per Share Improvement Reframe Rapport Therapeutics' (RAPP) Investment Narrative? - simplywall.st
All you need to know about Rapport Therapeutics, Inc. (RAPP) rating upgrade to buy - MSN
Third Rock Ventures v sells $5.38m in Rapport Therapeutics stock - Investing.com
TradingKey - TradingKey
Stifel reiterates Buy on Rapport Therapeutics stock, $56 target By Investing.com - Investing.com Canada
Rapport Therapeutics(RAPP.US) 10% Shareholder Sells US$11.09 Million in Common Stock - Moomoo
Third Rock funds trim Rapport Therapeutics (RAPP) stake under Rule 10b5-1 plan - Stock Titan
Third Rock sells shares of RAPP (NASDAQ: RAPP) under Form 144 - Stock Titan
Swedbank AB Buys Shares of 113,200 Rapport Therapeutics, Inc. $RAPP - MarketBeat
Third Rock sells 697,500 RAPP shares (RAPP) in April–May 2026 - Stock Titan
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: A 34% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Rapport Therapeutics (NASDAQ:RAPP) Posts Earnings Results, Beats Estimates By $0.25 EPS - MarketBeat
Third Rock Ventures sells 426,005 RAPP shares (NASDAQ: RAPP) - Stock Titan
Rapport Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Rapport Therapeutics Advances RAP-219 Into Phase 3, Setting Up New Catalyst in Focal Seizure Market - TipRanks
(RAPP) Volatility Zones as Tactical Triggers - Stock Traders Daily
Raymond James reiterates Strong Buy on Rapport Therapeutics stock By Investing.com - Investing.com Canada
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss - Yahoo Finance
Rapport Therapeutics (NASDAQ:RAPP) Beats Q1 Estimates, Guided by Strong Seizure Data and Accelerated Timelines - ChartMill
Earnings Flash (RAPP) Rapport Therapeutics, Inc. Reports Q1 Revenue $20.0M, vs. FactSet Est of $7.5M - marketscreener.com
Rapport Therapeutics, Inc. 1Q 2026: Revenue $20M, EPS $(0.42) — 10-Q Summary - TradingView
Collaboration deal lifts Rapport Therapeutics (NASDAQ: RAPP) revenue and cash - Stock Titan
Cash runway to 2H 2029 as Rapport (NASDAQ: RAPP) advances RAP-219 - Stock Titan
Seizure drug posted 90% cut as Rapport says cash lasts to 2029 - Stock Titan
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update - GlobeNewswire
Rapport Therapeutics Insiders Added US$1.61m Of Stock To Their Holdings - Yahoo Finance
Rapport Therapeutics (RAPP) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Third Rock Ventures Sells 17 Million Dollars in Rapport Therapeutics - HarianBasis.co
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near - AOL.com
Bullish Rapport Therapeutics Insiders Loaded Up On US$1.61m Of Stock - 富途牛牛
Price-Driven Insight from (RAPP) for Rule-Based Strategy - Stock Traders Daily
Rapport Therapeutics prices $250M stock at $26 per share - MSN
RAPP Should I Buy - Intellectia AI
Rapport Therapeutics, Inc. ($RAPP) CEO 2025 Pay Revealed - Quiver Quantitative
BTIG Research Reaffirms "Buy" Rating for Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), Danaher (DHR) and Intuitive Surgical (ISRG) - The Globe and Mail
Rapport Therapeutics (RAPP) outlines 2026 vote, board structure and executive pay - Stock Titan
Rapport Therapeutics Reports Sustained Seizure Reduction With RAP-219 in Phase 2a Focal Onset Seizure Trial at 2026 AAN Meeting - Minichart
Finanzdaten der Rapport Therapeutics Inc-Aktie (RAPP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rapport Therapeutics Inc-Aktie (RAPP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Third Rock Ventures V, L.P. | 10% Owner |
May 07 '26 |
Sale |
40.12 |
271,495 |
10,892,651 |
6,437,733 |
| Third Rock Ventures V, L.P. | 10% Owner |
May 08 '26 |
Sale |
40.31 |
5,018 |
202,256 |
6,432,715 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):